Becton, Dickinson and Company (BDX) Business News

Track Becton, Dickinson and Company in real time with a live news feed covering Becton, Dickinson and Company stock news, official press releases, company announcements, and an archive of historical Becton, Dickinson and Company news. ...more

  • Calendar
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
news photo
Loading...

STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITEâ„¢ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture FRANKLIN LAKES, N.J., Aug. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITEâ„¢ Scaffold in breast revision surgery for capsular contracture.

Read full article redirect
6:50 AM | Thursday | Aug 27, 2026

BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation

PRNewsWire

STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITEâ„¢ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture FRANKLIN LAKES, N.J., Aug. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITEâ„¢ Scaffold in breast revision surgery for capsular contracture.

Read full article arrow
News Thumbnail
6:50 AM | Thursday | Aug 27, 2026

BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation

PRNewsWire

STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITEâ„¢ Scaffold and generating evidence to support its use in breast revision surgery for capsular contracture FRANKLIN LAKES, N.J., Aug. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITEâ„¢ Scaffold in breast revision surgery for capsular contracture.

Read full article arrow
News Thumbnail
7:22 AM | Wednesday | Aug 26, 2026

BDX DCF Analysis: Intrinsic Value $157 vs Price $190

GuruFocus

On August 26, 2026, we conducted a DCF analysis for Becton Dickinson and Co (BDX), a company that has shown strong price performance recently with a 1-week increa

Read full article arrow
News Thumbnail
1:25 PM | Thursday | Aug 20, 2026

BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study

Zacks Investment Research

BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.

Read full article arrow
News Thumbnail
4:30 PM | Monday | Aug 17, 2026

BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire

PRNewsWire

FRANKLIN LAKES, N.J., Aug. 17, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8.

Read full article arrow
News Thumbnail
3:46 PM | Thursday | Aug 13, 2026

Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH

Zacks Investment Research

Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.

Read full article arrow
News Thumbnail
2:13 PM | Thursday | Aug 13, 2026

Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing

Seeking Alpha

Becton Dickinson gets its prior buy rating reaffirmed again, agreeing with the latest Wall St consensus. Key strengths are its diverse and growing clinical portfolio expected to drive further upside, while a favorable Fitch rating lowers balance sheet risk. Market performance vs the S&P 500 is improving again.

Read full article arrow
News Thumbnail
7:25 AM | Wednesday | Aug 12, 2026

BDX DCF Analysis: Intrinsic Value $141 vs Price $181

GuruFocus

On August 12, 2026, we delve into the DCF analysis for Becton Dickinson and Co (BDX), a company that has shown notable price performance recently, with a year-to-

Read full article arrow
News Thumbnail
6:50 AM | Wednesday | Aug 12, 2026

BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial

PRNewsWire

Enrollment completed in the first large-scale randomized study evaluating Phasixâ„¢ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery FRANKLIN LAKES, N.J., Aug. 12, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasixâ„¢ Mesh for the prevention of incisional hernias.

Read full article arrow
News Thumbnail
9:27 PM | Tuesday | Aug 11, 2026

First Eagle Investment Buys Becton Dickinson & Co (BDX) -- Shares Look 6% Undervalued on GF Value

GuruFocus

On June 30, 2026, First Eagle Investment (Trades, Portfolio) executed a significant add transaction for Becton Dickinson and Co (NYSE: BDX), increasing the firm's

Read full article arrow
News Thumbnail
9:45 AM | Monday | Aug 10, 2026

We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.

24/7 Wall Street

About a year ago, 24/7 Wall St. flagged four overlooked Dividend Aristocrats as stealth growth plays, arguing that boring income names carried real upside if the market ever noticed.

Read full article arrow
News Thumbnail